scPharmaceuticals, Inc. Aktie News

Shares of scPharmaceuticals have lost 37% over the past 3 years and are down 11% in 2025. Furoscix's subcutaneous administration offers the potential to keep heart failure patients at home longer and cut down on hospital readmissions. Q1 seasonality is in the rearview mirror, with multiple tailwinds, including Medicare redesign and label expansion, to fuel growth going forward.

scPharmaceuticals Inc. (NASDAQ:SCPH ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants William Thorpe - Investor Relations John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President of Commercial Rachael Nokes - Chief Financial Officer Conference Call Participants Roanna Ruiz - Leerink Partners Stacy Ku - TD Cowen Douglas Tsao - H.C. Wainwright Chas...

Generated net FUROSCIX ® revenue of $11.8 million in the first quarter of 2025 Formally launched FUROSCIX in second approved indication, Chronic Kidney Disease, in April 2025 Autoinjector on track for sNDA submission in Q3 2025; designed to reduce treatment time from five hours to less than ten seconds Cash and cash equivalents of $57.5 million as of March 31, 2025 Investor conference call and ...

Management to host conference call and webcast, after-market on May 14, 2025, at 4:30 p.m. ET Management to host conference call and webcast, after-market on May 14, 2025, at 4:30 p.m. ET

BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President and Chief Executive Officer, will participate in the following upcoming investor conferences:

scPharmaceuticals Inc. (NASDAQ:SCPH ) Q4 2024 Results Conference Call March 19, 2025 4:30 PM ET Company Participants Nick Colangelo - Investor Relations John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President of Commercial Rachael Nokes - Chief Financial Officer Conference Call Participants Stacy Ku - TD Cowen Glen Santangelo - Jefferies Roanna Ruiz - Leerink Partners Dougla...

scPharmaceuticals generated fourth quarter 2024 net FUROSCIX ® revenue of $12.2 million, and full year 2024 revenue of $36.3 million

Management to host conference call and webcast, after-market on March 19, 2025, at 4:30 p.m. ET Management to host conference call and webcast, after-market on March 19, 2025, at 4:30 p.m. ET